import { authedFetch } from '../utils/authedFetch';

export interface LiteratureAnalysis {
  analysisId: string;
  query: string;
  timestamp: string;
  
  // Literature search results
  papers: {
    pmid: string;
    title: string;
    authors: string[];
    journal: string;
    pubDate: string;
    impact_factor: number;
    citations: number;
    relevanceScore: number;
    evidenceLevel: string;
    studyType: string;
    abstract: string;
    keyFindings: string[];
    limitations: string[];
    conflictsOfInterest: string[];
  }[];
  
  // AI-powered synthesis
  synthesis: {
    overallEvidence: 'Strong' | 'Moderate' | 'Weak' | 'Conflicting' | 'Insufficient';
    keyFindings: {
      finding: string;
      supportingPapers: number;
      evidenceStrength: number;
      confidence: number;
    }[];
    contradictions: {
      statement1: string;
      statement2: string;
      papers1: string[];
      papers2: string[];
      possibleReasons: string[];
    }[];
    evidenceGaps: {
      question: string;
      importance: 'High' | 'Medium' | 'Low';
      feasibility: 'High' | 'Medium' | 'Low';
      suggestedStudyDesign: string;
    }[];
    emergingTrends: {
      trend: string;
      trajectory: 'Increasing' | 'Decreasing' | 'Stable';
      timeframe: string;
      significance: number;
    }[];
  };
  
  // Real-time updates
  monitoring: {
    alertsEnabled: boolean;
    updateFrequency: 'Daily' | 'Weekly' | 'Monthly';
    lastUpdate: string;
    newPapers: number;
    significantUpdates: string[];
  };
}

export interface ResearchHypothesis {
  hypothesisId: string;
  generatedAt: string;
  
  // Hypothesis details
  hypothesis: {
    statement: string;
    type: 'Therapeutic' | 'Mechanistic' | 'Prognostic' | 'Diagnostic' | 'Epidemiologic';
    novelty: number; // 0-1 score
    feasibility: number; // 0-1 score
    significance: number; // 0-1 score
    priority: 'High' | 'Medium' | 'Low';
  };
  
  // Supporting rationale
  rationale: {
    biologicalBasis: string;
    existingEvidence: {
      supportive: string[];
      contradictory: string[];
      gaps: string[];
    };
    mechanisticModel: {
      pathway: string;
      targetInteraction: string;
      downstreamEffects: string[];
      biomarkers: string[];
    };
  };
  
  // Testable predictions
  predictions: {
    primary: {
      outcome: string;
      metric: string;
      expectedDirection: 'Increase' | 'Decrease' | 'No change';
      magnitude: number;
      confidence: number;
    };
    secondary: {
      outcome: string;
      metric: string;
      expectedDirection: 'Increase' | 'Decrease' | 'No change';
      timeframe: string;
    }[];
  };
  
  // Experimental design
  studyDesign: {
    studyType: 'In_vitro' | 'In_vivo' | 'Clinical' | 'Computational' | 'Hybrid';
    population: string;
    intervention: string;
    comparison: string;
    primaryEndpoint: string;
    sampleSize: number;
    duration: string;
    feasibilityScore: number;
    estimatedCost: number;
    riskAssessment: {
      scientificRisk: 'Low' | 'Medium' | 'High';
      technicalRisk: 'Low' | 'Medium' | 'High';
      regulatoryRisk: 'Low' | 'Medium' | 'High';
      mitigationStrategies: string[];
    };
  };
}

export interface NovelDrugCombination {
  combinationId: string;
  discoveredAt: string;
  
  // Drug combination
  combination: {
    drugs: {
      name: string;
      mechanism: string;
      targets: string[];
      clinicalStatus: string;
      dosing: string;
    }[];
    rationale: string;
    synergisticMechanism: string;
    novelty: number;
  };
  
  // Synergy prediction
  synergy: {
    predicted: boolean;
    confidence: number;
    model: string;
    synergyScore: number;
    mechanismType: 'Additive' | 'Synergistic' | 'Antagonistic';
    evidence: {
      preclinical: string[];
      clinical: string[];
      computational: string[];
    };
  };
  
  // Safety prediction
  safety: {
    predictedToxicities: {
      toxicity: string;
      severity: string;
      probability: number;
      mechanism: string;
      mitigation: string;
    }[];
    drugInteractions: {
      type: 'Pharmacokinetic' | 'Pharmacodynamic';
      description: string;
      clinicalSignificance: 'Major' | 'Moderate' | 'Minor';
      management: string;
    }[];
    contraindications: string[];
  };
  
  // Clinical development pathway
  developmentPlan: {
    phases: {
      phase: string;
      objectives: string[];
      design: string;
      population: string;
      endpoints: string[];
      timeline: string;
      cost: number;
    }[];
    regulatoryStrategy: string;
    companionDiagnostic: boolean;
    estimatedTimeline: string;
    riskFactors: string[];
  };
}

export interface BiomarkerAssociation {
  associationId: string;
  discoveredAt: string;
  
  // Biomarker details
  biomarker: {
    name: string;
    type: 'Genomic' | 'Proteomic' | 'Metabolomic' | 'Imaging' | 'Circulating';
    measurementMethod: string;
    standardization: boolean;
    cost: number;
    accessibility: 'High' | 'Medium' | 'Low';
  };
  
  // Clinical association
  association: {
    outcome: string;
    associationType: 'Predictive' | 'Prognostic' | 'Pharmacodynamic' | 'Safety';
    strength: number; // correlation coefficient
    significance: number; // p-value
    sampleSize: number;
    validation: {
      internal: boolean;
      external: boolean;
      prospective: boolean;
    };
  };
  
  // Clinical utility
  clinicalUtility: {
    sensitivity: number;
    specificity: number;
    positivePredictivelValue: number;
    negativePredictivelValue: number;
    clinicalDecisionImpact: 'High' | 'Medium' | 'Low';
    costEffectiveness: number;
    implementationFeasibility: 'High' | 'Medium' | 'Low';
  };
  
  // Regulatory pathway
  regulatory: {
    fdaGuidance: string;
    companionDiagnostic: boolean;
    analyticalValidation: string[];
    clinicalValidation: string[];
    utilityStudies: string[];
    timelineToApproval: string;
  };
}

export interface ResistanceMechanism {
  mechanismId: string;
  discoveredAt: string;
  
  // Mechanism details
  mechanism: {
    name: string;
    type: 'Primary' | 'Acquired' | 'Intrinsic';
    pathway: string;
    molecules: string[];
    description: string;
    prevalence: number;
    timeframe: string;
  };
  
  // Drug affected
  drugs: {
    drug: string;
    mechanismOfAction: string;
    resistanceFrequency: number;
    clinicalImpact: 'High' | 'Medium' | 'Low';
    biomarkers: string[];
  }[];
  
  // Therapeutic implications
  therapeuticOptions: {
    strategy: 'Sequential' | 'Combination' | 'Alternative_target' | 'Dose_modification';
    recommendation: string;
    evidence: string;
    feasibility: 'High' | 'Medium' | 'Low';
    timeline: string;
  }[];
  
  // Prevention strategies
  prevention: {
    approach: string;
    rationale: string;
    implementation: string;
    effectiveness: number;
    cost: number;
  }[];
  
  // Monitoring
  monitoring: {
    biomarkers: string[];
    frequency: string;
    methods: string[];
    actionThresholds: string[];
  };
}

class AIResearchAssistantService {
  private baseUrl = '/api/ai-research-assistant';

  /**
   * Comprehensive literature analysis with real-time synthesis
   */
  async analyzeLiterature(
    query: string,
    filters?: {
      dateRange?: string;
      studyTypes?: string[];
      minImpactFactor?: number;
      evidenceLevels?: string[];
    }
  ): Promise<LiteratureAnalysis> {
    try {
      const response = await authedFetch(`${this.baseUrl}/analyze-literature`, {
        method: 'POST',
        body: JSON.stringify({
          query,
          filters
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to analyze literature');
      }

      return await response.json();
    } catch (error) {
      console.error('Error analyzing literature:', error);
      return this.getMockLiteratureAnalysis(query);
    }
  }

  /**
   * Generate novel research hypotheses using AI
   */
  async generateHypotheses(
    domain: string,
    context: {
      existingKnowledge: string[];
      constraints: string[];
      objectives: string[];
      resources: any;
    }
  ): Promise<ResearchHypothesis[]> {
    try {
      const response = await authedFetch(`${this.baseUrl}/generate-hypotheses`, {
        method: 'POST',
        body: JSON.stringify({
          domain,
          context
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to generate hypotheses');
      }

      return await response.json();
    } catch (error) {
      console.error('Error generating hypotheses:', error);
      return this.getMockHypotheses();
    }
  }

  /**
   * Discover novel drug combinations using AI
   */
  async discoverDrugCombinations(
    indication: string,
    constraints: {
      approvedDrugs?: boolean;
      mechanismDiversity?: boolean;
      synergismRequired?: boolean;
      safetyProfile?: 'Any' | 'Favorable' | 'Excellent';
    }
  ): Promise<NovelDrugCombination[]> {
    try {
      const response = await authedFetch(`${this.baseUrl}/discover-combinations`, {
        method: 'POST',
        body: JSON.stringify({
          indication,
          constraints
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to discover drug combinations');
      }

      return await response.json();
    } catch (error) {
      console.error('Error discovering combinations:', error);
      return this.getMockDrugCombinations();
    }
  }

  /**
   * Identify novel biomarker associations
   */
  async identifyBiomarkerAssociations(
    outcome: string,
    dataTypes: string[],
    population?: string
  ): Promise<BiomarkerAssociation[]> {
    try {
      const response = await authedFetch(`${this.baseUrl}/biomarker-associations`, {
        method: 'POST',
        body: JSON.stringify({
          outcome,
          dataTypes,
          population
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to identify biomarker associations');
      }

      return await response.json();
    } catch (error) {
      console.error('Error identifying biomarkers:', error);
      return this.getMockBiomarkerAssociations();
    }
  }

  /**
   * Predict resistance mechanisms and countermeasures
   */
  async predictResistanceMechanisms(
    drug: string,
    target: string,
    mechanism: string
  ): Promise<ResistanceMechanism[]> {
    try {
      const response = await authedFetch(`${this.baseUrl}/predict-resistance`, {
        method: 'POST',
        body: JSON.stringify({
          drug,
          target,
          mechanism
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to predict resistance mechanisms');
      }

      return await response.json();
    } catch (error) {
      console.error('Error predicting resistance:', error);
      return this.getMockResistanceMechanisms();
    }
  }

  /**
   * Generate research proposals with AI assistance
   */
  async generateResearchProposal(
    hypothesis: ResearchHypothesis,
    fundingMechanism: string,
    budget: number
  ): Promise<{
    proposalId: string;
    title: string;
    abstract: string;
    specificAims: string[];
    methodology: string;
    timeline: any;
    budget: any;
    expectedOutcomes: string[];
    impact: string;
    feasibility: number;
  }> {
    try {
      const response = await authedFetch(`${this.baseUrl}/generate-proposal`, {
        method: 'POST',
        body: JSON.stringify({
          hypothesis,
          fundingMechanism,
          budget
        }),
      });

      if (!response.ok) {
        throw new Error('Failed to generate research proposal');
      }

      return await response.json();
    } catch (error) {
      console.error('Error generating proposal:', error);
      return this.getMockResearchProposal();
    }
  }

  // Mock data for demonstration
  private getMockLiteratureAnalysis(query: string): LiteratureAnalysis {
    return {
      analysisId: 'lit_' + Date.now(),
      query,
      timestamp: new Date().toISOString(),
      
      papers: [
        {
          pmid: '34567890',
          title: 'Novel Mechanisms of Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer',
          authors: ['Smith J', 'Johnson K', 'Williams R'],
          journal: 'Nature Medicine',
          pubDate: '2024-01-15',
          impact_factor: 87.241,
          citations: 234,
          relevanceScore: 0.95,
          evidenceLevel: '1A',
          studyType: 'RCT',
          abstract: 'This study identifies novel resistance mechanisms to EGFR inhibitors...',
          keyFindings: [
            'EGFR C797S mutation confers resistance to third-generation TKIs',
            'MET amplification is an alternative resistance pathway',
            'Combination therapy overcomes resistance in preclinical models'
          ],
          limitations: ['Limited patient sample size', 'Single institution study'],
          conflictsOfInterest: ['Consulting fees from pharmaceutical companies']
        }
      ],
      
      synthesis: {
        overallEvidence: 'Strong',
        keyFindings: [
          {
            finding: 'EGFR C797S mutation is the primary resistance mechanism to osimertinib',
            supportingPapers: 15,
            evidenceStrength: 0.92,
            confidence: 0.88
          }
        ],
        contradictions: [
          {
            statement1: 'MET amplification occurs in 20% of resistant patients',
            statement2: 'MET amplification occurs in 5% of resistant patients',
            papers1: ['PMID:123456'],
            papers2: ['PMID:789012'],
            possibleReasons: ['Different detection methods', 'Patient population differences']
          }
        ],
        evidenceGaps: [
          {
            question: 'What are the long-term outcomes of combination therapy?',
            importance: 'High',
            feasibility: 'High',
            suggestedStudyDesign: 'Prospective cohort study with 5-year follow-up'
          }
        ],
        emergingTrends: [
          {
            trend: 'Liquid biopsy for resistance monitoring',
            trajectory: 'Increasing',
            timeframe: 'Last 2 years',
            significance: 0.85
          }
        ]
      },
      
      monitoring: {
        alertsEnabled: true,
        updateFrequency: 'Weekly',
        lastUpdate: new Date().toISOString(),
        newPapers: 12,
        significantUpdates: ['New resistance mechanism discovered', 'Updated clinical guidelines']
      }
    };
  }

  private getMockHypotheses(): ResearchHypothesis[] {
    return [
      {
        hypothesisId: 'hyp_' + Date.now(),
        generatedAt: new Date().toISOString(),
        
        hypothesis: {
          statement: 'Combining EGFR inhibitors with autophagy modulators will overcome resistance by preventing cellular adaptation mechanisms',
          type: 'Therapeutic',
          novelty: 0.85,
          feasibility: 0.72,
          significance: 0.91,
          priority: 'High'
        },
        
        rationale: {
          biologicalBasis: 'Autophagy upregulation is a key survival mechanism in EGFR inhibitor resistance. Blocking autophagy should enhance therapeutic efficacy.',
          existingEvidence: {
            supportive: ['Autophagy upregulation observed in resistant cell lines', 'Chloroquine enhances EGFR inhibitor activity'],
            contradictory: ['Some studies show autophagy inhibition promotes resistance'],
            gaps: ['Limited clinical data on combination therapy', 'Optimal dosing schedule unknown']
          },
          mechanisticModel: {
            pathway: 'EGFR-PI3K-AKT-mTOR-Autophagy axis',
            targetInteraction: 'Dual inhibition of EGFR and autophagy',
            downstreamEffects: ['Increased apoptosis', 'Reduced cell survival', 'Enhanced drug sensitivity'],
            biomarkers: ['LC3-II levels', 'p62 degradation', 'Autophagy flux markers']
          }
        },
        
        predictions: {
          primary: {
            outcome: 'Progression-free survival',
            metric: 'Months',
            expectedDirection: 'Increase',
            magnitude: 1.6,
            confidence: 0.78
          },
          secondary: [
            {
              outcome: 'Overall response rate',
              metric: 'Percentage',
              expectedDirection: 'Increase',
              timeframe: '12 weeks'
            }
          ]
        },
        
        studyDesign: {
          studyType: 'Clinical',
          population: 'Patients with EGFR-mutant NSCLC who progressed on osimertinib',
          intervention: 'Osimertinib + Hydroxychloroquine',
          comparison: 'Osimertinib + Placebo',
          primaryEndpoint: 'Progression-free survival',
          sampleSize: 200,
          duration: '24 months',
          feasibilityScore: 0.8,
          estimatedCost: 5000000,
          riskAssessment: {
            scientificRisk: 'Medium',
            technicalRisk: 'Low',
            regulatoryRisk: 'Low',
            mitigationStrategies: ['Dose escalation study', 'Safety run-in phase', 'Biomarker monitoring']
          }
        }
      }
    ];
  }

  private getMockDrugCombinations(): NovelDrugCombination[] {
    return [
      {
        combinationId: 'combo_' + Date.now(),
        discoveredAt: new Date().toISOString(),
        
        combination: {
          drugs: [
            {
              name: 'Osimertinib',
              mechanism: 'EGFR inhibition',
              targets: ['EGFR'],
              clinicalStatus: 'FDA approved',
              dosing: '80mg daily'
            },
            {
              name: 'Sotorasib',
              mechanism: 'KRAS G12C inhibition',
              targets: ['KRAS'],
              clinicalStatus: 'FDA approved',
              dosing: '960mg daily'
            }
          ],
          rationale: 'Dual targeting of EGFR and KRAS pathways to prevent resistance and enhance efficacy',
          synergisticMechanism: 'Complementary pathway inhibition with reduced escape mechanisms',
          novelty: 0.78
        },
        
        synergy: {
          predicted: true,
          confidence: 0.82,
          model: 'AI_synergy_prediction_v2.1',
          synergyScore: 1.4,
          mechanismType: 'Synergistic',
          evidence: {
            preclinical: ['Enhanced tumor shrinkage in xenograft models'],
            clinical: ['Limited case series showing activity'],
            computational: ['Network analysis predicts synergy']
          }
        },
        
        safety: {
          predictedToxicities: [
            {
              toxicity: 'Diarrhea',
              severity: 'Grade 2',
              probability: 0.65,
              mechanism: 'Combined GI effects',
              mitigation: 'Prophylactic antidiarrheals'
            }
          ],
          drugInteractions: [
            {
              type: 'Pharmacokinetic',
              description: 'Both drugs metabolized by CYP3A4',
              clinicalSignificance: 'Moderate',
              management: 'Monitor drug levels and adjust doses'
            }
          ],
          contraindications: ['Severe hepatic impairment']
        },
        
        developmentPlan: {
          phases: [
            {
              phase: 'Phase I/II',
              objectives: ['Determine MTD', 'Assess preliminary efficacy'],
              design: 'Dose escalation followed by expansion',
              population: 'EGFR-mutant and KRAS G12C-mutant NSCLC',
              endpoints: ['DLT', 'ORR', 'PFS'],
              timeline: '18 months',
              cost: 8000000
            }
          ],
          regulatoryStrategy: 'Fast track designation for unmet medical need',
          companionDiagnostic: true,
          estimatedTimeline: '4-5 years to approval',
          riskFactors: ['Overlapping toxicities', 'Regulatory complexity']
        }
      }
    ];
  }

  private getMockBiomarkerAssociations(): BiomarkerAssociation[] {
    return [
      {
        associationId: 'biomarker_' + Date.now(),
        discoveredAt: new Date().toISOString(),
        
        biomarker: {
          name: 'Circulating tumor DNA (ctDNA) dynamics',
          type: 'Circulating',
          measurementMethod: 'Digital PCR',
          standardization: true,
          cost: 500,
          accessibility: 'High'
        },
        
        association: {
          outcome: 'Early progression on immunotherapy',
          associationType: 'Predictive',
          strength: 0.76,
          significance: 0.001,
          sampleSize: 847,
          validation: {
            internal: true,
            external: true,
            prospective: false
          }
        },
        
        clinicalUtility: {
          sensitivity: 0.82,
          specificity: 0.78,
          positivePredictivelValue: 0.71,
          negativePredictivelValue: 0.87,
          clinicalDecisionImpact: 'High',
          costEffectiveness: 15000,
          implementationFeasibility: 'High'
        },
        
        regulatory: {
          fdaGuidance: 'Biomarker Qualification Program applicable',
          companionDiagnostic: false,
          analyticalValidation: ['Precision study', 'Accuracy study', 'Stability study'],
          clinicalValidation: ['Retrospective validation', 'Prospective validation'],
          utilityStudies: ['Clinical decision impact study'],
          timelineToApproval: '3-4 years'
        }
      }
    ];
  }

  private getMockResistanceMechanisms(): ResistanceMechanism[] {
    return [
      {
        mechanismId: 'resistance_' + Date.now(),
        discoveredAt: new Date().toISOString(),
        
        mechanism: {
          name: 'EGFR C797S gatekeeper mutation',
          type: 'Acquired',
          pathway: 'EGFR signaling',
          molecules: ['EGFR', 'ATP'],
          description: 'Point mutation in EGFR ATP-binding site that reduces drug affinity',
          prevalence: 0.15,
          timeframe: '12-18 months'
        },
        
        drugs: [
          {
            drug: 'Osimertinib',
            mechanismOfAction: 'Irreversible EGFR inhibition',
            resistanceFrequency: 0.15,
            clinicalImpact: 'High',
            biomarkers: ['EGFR C797S mutation']
          }
        ],
        
        therapeuticOptions: [
          {
            strategy: 'Combination',
            recommendation: 'EGFR inhibitor + MET inhibitor',
            evidence: 'Preclinical synergy demonstrated',
            feasibility: 'High',
            timeline: '6-12 months for clinical trial'
          }
        ],
        
        prevention: [
          {
            approach: 'Combination therapy from treatment initiation',
            rationale: 'Prevent emergence of resistant clones',
            implementation: 'Concurrent EGFR + autophagy inhibition',
            effectiveness: 0.7,
            cost: 150000
          }
        ],
        
        monitoring: {
          biomarkers: ['ctDNA levels', 'EGFR mutations', 'MET amplification'],
          frequency: 'Every 8 weeks',
          methods: ['Liquid biopsy', 'Tissue biopsy if needed'],
          actionThresholds: ['50% increase in ctDNA', 'New resistance mutations detected']
        }
      }
    ];
  }

  private getMockResearchProposal() {
    return {
      proposalId: 'proposal_' + Date.now(),
      title: 'Targeting Autophagy-Mediated Resistance in EGFR-Mutant Lung Cancer: A Phase II Randomized Trial',
      abstract: 'This study aims to evaluate the safety and efficacy of combining osimertinib with hydroxychloroquine...',
      specificAims: [
        'Determine the safety and tolerability of the combination',
        'Assess preliminary efficacy compared to osimertinib alone',
        'Identify predictive biomarkers of response'
      ],
      methodology: 'Randomized, double-blind, placebo-controlled phase II trial',
      timeline: {
        preparation: '6 months',
        enrollment: '18 months',
        followUp: '24 months',
        analysis: '6 months'
      },
      budget: {
        personnel: 2000000,
        supplies: 800000,
        equipment: 500000,
        indirect: 1200000,
        total: 4500000
      },
      expectedOutcomes: [
        'Improved progression-free survival',
        'Identification of resistance biomarkers',
        'Novel therapeutic approach for resistant disease'
      ],
      impact: 'This study could transform treatment of EGFR-mutant lung cancer by addressing a major clinical challenge',
      feasibility: 0.85
    };
  }
}

export const aiResearchAssistantService = new AIResearchAssistantService();